Introduction: The probability of making mistakes in the prescription of medicines is high in pediatrics, and substantially increases in emergency situations.
Material And Methods: This prospective observational study analyzed the prescriptions issued by physicians during 23 cardiopulmonary resuscitation pediatric emergency training sessions.
Results: During 94 simulated cases, 96 physicians participated. Forty-four prescriptions on paper were analyzed (48%) including 120 doses. Twelve medication errors were found (10%, CI 95%: 5.517.2). Stress was identified as the primary cause of prescription mistakes.
Conclusions: Drug prescription mistakes frequently occurred during pediatric emergency simulations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5546/aap.2017.294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacovigilance insights into medication-induced risk of dural arteriovenous fistula.
Int J Surg
January 2025
Department of Orthopedics, Civil Aviation General Hospital, Beijing, China.
Background: Dural arteriovenous fistulas (DAVFs) pose a significant health threat owing to their high misdiagnosis rate. Case reports suggest that DAVFs or related acute events may follow medication use; however, drug-related risk factors remain unclear. In clinical practice, the concomitant use of multiple drugs for therapy is known as "polypharmacy situations," further increasing the risk of drug-induced DAVF.
View Article and Find Full Text PDFThe prevalence and consequences of support for off-label Ozempic prescriptions.
Health Econ Policy Law
January 2025
Department of Political Science, Texas A&M University, College Station, TX, USA.
Ozempic and related semaglutide drugs represent a popular new strategy to address obesity in the United States, yet uptake of these medications has sparked opposition highlighting concerns about off-label drug use policies, drug safety, supply shortages and cost. Public attitudes towards off-label prescribing by physicians broadly, and towards Ozempic in particular, in light of this opposition are unclear. To better understand public sentiment on this topic, we analysed data from a representative survey of 3,420 US adults conducted from 13 to 22 June 2023.
View Article and Find Full Text PDFPatterns of outpatient proton‒pump inhibitors use among older adults in a duplicative health system: comparing public and private prescribing.
BMC Health Serv Res
January 2025
NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal.
Background: Proton-pump-inhibitors (PPIs) are overprescribed, posing challenges to patients and healthcare systems. In Portugal, the public National Health Service (NHS) provides universal coverage and reimburses medication regardless of prescription origin, i.e.
View Article and Find Full Text PDFConcomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review.
Med Oncol
January 2025
Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan, China.
In the past decade, a variety of immune checkpoint inhibitors (ICIs) are currently approved for lung cancer in the world. As a new therapeutic approach, ICIs have shown significant clinical benefits in the first-line or second-line treatment for advanced lung cancer, improving the survival and quality of life of patients. Patients need to take multiple drugs in the meantime due to their own disease or side effects during treatment.
View Article and Find Full Text PDFAdherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy.
Eur Heart J Qual Care Clin Outcomes
January 2025
University of Milano-Bicocca (Emeritus Professor), Milan, Italy.
Aims: To compare adherence to perindopril/amlodipine/atorvastatin combination administrated as a polypill (one pill) vs separate tablets.
Methods: Using the healthcare utilization database of Lombardy (Italy), 1 110 patients who received the perindopril/amlodipine/atorvastatin polypill during 2019-2021 were matched with 1 110 patients prescribed the same combination in separate tablets or as two antihypertensive drugs in a single tablet and the lipid-lowering drug tablet separately. Adherence to treatment was assessed over the year after the first perindopril/amlodipine/atorvastatin dispensation as the proportion of the follow-up days covered by prescription (PDC).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!